Title :

SARS-CoV-2 versus influenza associated acute respiratory distress syndrome requiring veno-venous extracorporeal membrane oxygenation support.

Author(s) :

Cousin, Nicolas [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Bourel, Claire [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Carpentier, Dorothee [Auteur]
CHU Rouen
GOUTAY, Julien [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Mugnier, Agnes [Auteur]
Institut Coeur Poumon [CHU Lille]
Labreuche, Julien [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Godeau, Elise [Auteur]
Clavier, Thomas [Auteur]
CHU Rouen
Grange, Steven [Auteur]
Service de Soins Intensifs [CHU Rouen]
Tamion, Fabienne [Auteur]
Service de Soins Intensifs [CHU Rouen]
Durand, Arthur [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Moussa, Mouhamed [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Duburcq, Thibault [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]

Journal title :

ASAIO Journal

Abbreviated title :

ASAIO J

Volume number :

67

Pages :

125-131

Publication date :

2020-10-24

ISSN :

1538-943X

English keyword(s) :

COVID-19
acute respiratory distress syndrome
extracorporeal membrane oxygenation
influenza

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

No study has compared patients with COVID-19-related refractory ARDS requiring veno-venous extracorporeal membrane oxygenation (V-V ECMO) to a relevant and homogenous control population. We aimed to compare the outcomes, ...
Show more >No study has compared patients with COVID-19-related refractory ARDS requiring veno-venous extracorporeal membrane oxygenation (V-V ECMO) to a relevant and homogenous control population. We aimed to compare the outcomes, the clinical characteristics, and the adverse effects of COVID-19 patients to a retrospective cohort of influenza patients. This retrospective case-control study was conducted in the ICUs of Lille and Rouen University Hospitals between January 2014 and May 2020. Two independent cohorts of patients with ARDS requiring V-V ECMO infected with either COVID-19 (n = 30) or influenza (n = 22) were compared. A 3-month follow-up was completed for all patients. Median age of COVID-19 and influenza patients was similar (57 vs. 55 years; p = 0.62). The 28-day mortality rate did not significantly differ between COVID-19 (43.3%) and influenza patients (50%, p = 0.63). There was no significant difference considering the cumulative incidence of ECMO weaning, hospital discharge, and 3-month survival. COVID-19 patients had a lower SAPS II score (58 [37–64] vs. 68 [52–83]; p = 0.039), a higher body mass index (33 [29–38] vs. 30 [26–34] kg/m2; p = 0.05), and were cannulated later (median delay between mechanical support and V-V ECMO 6 vs. 3 days, p = 0.004) compared with influenza patients. No difference in overall adverse events was observed between COVID-19 and influenza patients (70% vs. 95.5% respectively; p = 0.23). Despite differences in clinical presentation before V-V ECMO implantation, 28-day and 3-month mortality rate did not differ between COVID-19 and influenza patients. Considering the lack of specific treatment for COVID-19, V-V ECMO should be considered as a relevant rescue organ support.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2023-11-15T07:58:33Z
2024-01-11T08:18:20Z